Mon, Dec 11, 2023
Volume 17, Issue 4 (July-August 2018)                   Payesh 2018, 17(4): 399-407 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ramin Mozafari kermani, Ahmad Ahmadi, Jila Sedighi, Mahmoud Tavoussi, Aliasghar Haeri Mehrizi, Rahele Rostami et al . Evaluation of the Incidence of Neurodevelopmental Disorders in Children Aged 1 to 3 Years with Congenital Hypothyroidism Treated with Levothyroxine. Payesh 2018; 17 (4) :399-407
1- Health Metrics Research Center, Institute for Health Sciences Research, ACECR, Tehran, Iran
2- Fellowship of Pediatric Endocrine.Baghiatollah Hospital, Tehran, Iran
3- Health Metrics Research Center, Institute for Health Sciences Research, ACECR, Tehran, Iran4. Mahmoud Tavoussi
4- Nursing student at the Faculty of nursing, Aja University of Medical Sciences
Abstract:   (4111 Views)
Objective (s): To assess the incidence of neurodevelopmental disorders in children aged 1 to 3 years with congenital hypothyroidism treated with Levothyroxine.
Methods: In a historical cohort study, 122 neonates with congenital hypothyroidism under treatment with levothyroxine and 122 healthy children aged between one and three years were evaluated by the ASQ questionnaire for their neurodevelopmental status. Sampling was done non-randomly. In the exposure group, questionnaires were asked by telephone or they were invited to the clinic for an assessment period after contact with them. In the healthy children group (control group), children who were referred to the clinic for periodic examinations were selected.
Results: Overall 17.2% of children with congenital hypothyroidism and 12.3% of health children failed to obtain tershold score for developmental test giving a relative risk of 1.4, but the risk was was not significant.
Conclusion: The study showed that children with congenital hypothyroidism would develop normally if diagnosis and initiation of treatment starts at age under one month. The prescribed dose of 10 micrograms per kilogram of baby weight at the start of treatment and adjusting the dosage of the drug correlate with the age and weight of the child and continuing until the age of three, will lead to normal development in children.
Full-Text [PDF 812 kb]   (894 Downloads)    
type of study: Descriptive |
Accepted: 2018/06/17 | ePublished ahead of print: 2018/07/28 | Published: 2018/07/15

Add your comments about this article : Your username or Email:

Rights and Permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 All Rights Reserved | Payesh (Health Monitor)

Designed & Developed by : Yektaweb